SGD treatment over 42 days was observed to increase SOD, CAT, and GSH-Px levels and decrease HDL-C levels in rats in the SGD group when compared with rats in the STZ group, respectively (P < 0.05 or P < 0.01). The gene discussed is SOD1; the disease is specific granule deficiency.